×
S&P 500   3,805.92 (-0.51%)
DOW   30,765.65 (-1.07%)
QQQ   283.58 (+0.51%)
AAPL   140.04 (+0.80%)
MSFT   259.21 (-0.14%)
META   165.01 (+3.11%)
GOOGL   2,238.76 (+2.94%)
AMZN   112.77 (+2.93%)
TSLA   687.18 (+0.79%)
NVDA   147.75 (+1.74%)
NIO   21.73 (+1.73%)
BABA   116.70 (+0.60%)
AMD   74.14 (+0.64%)
MU   55.78 (+3.97%)
CGC   2.65 (-5.69%)
T   20.95 (-1.69%)
GE   61.14 (-3.78%)
F   11.05 (-2.39%)
DIS   96.07 (-0.07%)
AMC   12.58 (-7.02%)
PFE   51.01 (-2.49%)
PYPL   73.56 (+3.03%)
NFLX   183.15 (+1.78%)
S&P 500   3,805.92 (-0.51%)
DOW   30,765.65 (-1.07%)
QQQ   283.58 (+0.51%)
AAPL   140.04 (+0.80%)
MSFT   259.21 (-0.14%)
META   165.01 (+3.11%)
GOOGL   2,238.76 (+2.94%)
AMZN   112.77 (+2.93%)
TSLA   687.18 (+0.79%)
NVDA   147.75 (+1.74%)
NIO   21.73 (+1.73%)
BABA   116.70 (+0.60%)
AMD   74.14 (+0.64%)
MU   55.78 (+3.97%)
CGC   2.65 (-5.69%)
T   20.95 (-1.69%)
GE   61.14 (-3.78%)
F   11.05 (-2.39%)
DIS   96.07 (-0.07%)
AMC   12.58 (-7.02%)
PFE   51.01 (-2.49%)
PYPL   73.56 (+3.03%)
NFLX   183.15 (+1.78%)
S&P 500   3,805.92 (-0.51%)
DOW   30,765.65 (-1.07%)
QQQ   283.58 (+0.51%)
AAPL   140.04 (+0.80%)
MSFT   259.21 (-0.14%)
META   165.01 (+3.11%)
GOOGL   2,238.76 (+2.94%)
AMZN   112.77 (+2.93%)
TSLA   687.18 (+0.79%)
NVDA   147.75 (+1.74%)
NIO   21.73 (+1.73%)
BABA   116.70 (+0.60%)
AMD   74.14 (+0.64%)
MU   55.78 (+3.97%)
CGC   2.65 (-5.69%)
T   20.95 (-1.69%)
GE   61.14 (-3.78%)
F   11.05 (-2.39%)
DIS   96.07 (-0.07%)
AMC   12.58 (-7.02%)
PFE   51.01 (-2.49%)
PYPL   73.56 (+3.03%)
NFLX   183.15 (+1.78%)
S&P 500   3,805.92 (-0.51%)
DOW   30,765.65 (-1.07%)
QQQ   283.58 (+0.51%)
AAPL   140.04 (+0.80%)
MSFT   259.21 (-0.14%)
META   165.01 (+3.11%)
GOOGL   2,238.76 (+2.94%)
AMZN   112.77 (+2.93%)
TSLA   687.18 (+0.79%)
NVDA   147.75 (+1.74%)
NIO   21.73 (+1.73%)
BABA   116.70 (+0.60%)
AMD   74.14 (+0.64%)
MU   55.78 (+3.97%)
CGC   2.65 (-5.69%)
T   20.95 (-1.69%)
GE   61.14 (-3.78%)
F   11.05 (-2.39%)
DIS   96.07 (-0.07%)
AMC   12.58 (-7.02%)
PFE   51.01 (-2.49%)
PYPL   73.56 (+3.03%)
NFLX   183.15 (+1.78%)
NASDAQ:ARCT

Arcturus Therapeutics Stock Forecast, Price & News

$18.28
+2.12 (+13.12%)
(As of 07/5/2022 02:22 PM ET)
Add
Compare
Today's Range
$15.55
$18.51
50-Day Range
$12.26
$22.59
52-Week Range
$11.70
$65.00
Volume
25,162 shs
Average Volume
811,596 shs
Market Capitalization
$482.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.75

Arcturus Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
117.1% Upside
$39.75 Price Target
Short Interest
Bearish
14.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Arcturus Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.66) to $2.00 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.59 out of 5 stars

Medical Sector

712th out of 1,428 stocks

Pharmaceutical Preparations Industry

351st out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Arcturus Therapeutics logo

About Arcturus Therapeutics (NASDAQ:ARCT) Stock

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

ARCT Stock News Headlines

Arcturus Therapeutics Tops Q1 EPS by 338c
Arcturus Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
177
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/05/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$39.75
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+117.5%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
7 Analysts

Profitability

Net Income
$-203,700,000.00
Net Margins
-1,282.62%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.40 million
Book Value
$16.19 per share

Miscellaneous

Free Float
23,196,000
Market Cap
$482.96 million
Optionable
Optionable
Beta
2.79














Arcturus Therapeutics Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics
or view top-rated stocks.

What is Arcturus Therapeutics' stock price forecast for 2022?

7 equities research analysts have issued 12 month price targets for Arcturus Therapeutics' stock. Their ARCT stock forecasts range from $8.00 to $105.00. On average, they anticipate Arcturus Therapeutics' share price to reach $39.75 in the next twelve months. This suggests a possible upside of 119.4% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Arcturus Therapeutics' stock performed in 2022?

Arcturus Therapeutics' stock was trading at $37.01 on January 1st, 2022. Since then, ARCT stock has decreased by 51.0% and is now trading at $18.12.
View the best growth stocks for 2022 here
.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Arcturus Therapeutics
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its earnings results on Monday, May, 9th. The biotechnology company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.29) by $0.65. The biotechnology company had revenue of $5.24 million for the quarter, compared to the consensus estimate of $3.26 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 64.94% and a negative net margin of 1,282.62%. During the same period last year, the company posted ($2.15) EPS.
View Arcturus Therapeutics' earnings history
.

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 50, Pay $960k)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 43, Pay $750k)
  • Mr. Andrew H. Sassine MBA, CFO & Director (Age 58, Pay $750k)
  • Mr. Lance Kurata, Chief Legal Officer
  • Dr. Steven George Hughes M.B.A., M.D., Strategic Clinical Advisor & Member of Scientific Advisory Board (Age 54, Pay $644k)
  • Mr. Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller
  • Dr. Dushyant B. Varshney Ph.D., Exec. VP & Chief Technology Officer
  • Mr. Deepankar Roy, Sr. Director of Investor Relations
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Dr. Kelly A. Lindert M.D., Chief Devel. Officer of Vaccines

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $18.12.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $478.73 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203,700,000.00 in net income (profit) each year or ($7.53) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

Arcturus Therapeutics employs 177 workers across the globe.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for Arcturus Therapeutics is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com.

This page (NASDAQ:ARCT) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.